Ronald F. Pfeiffer, Ph.D.

Ronald F. Pfeiffer, Ph.D.

Professor
Department of Neurology


The University of Tennessee Health Science Center
855 Monroe Avenue, Room 415
Memphis, TN 38163
Phone: (901) 448-6811
Fax: (901) 448-7440
Email: Ronald F. Pfeiffer



Education

  • M.D. Institution: University of Nebraska Medical Center
  • Postdoctoral: Walter Reed Army Medical Center

Link

Research Interests

The primary focus of my research is on Parkinson's disease. Clinical trials of experimental antiparkinson medications are an ongoing facet of the research program. Gastrointestinal dysfunction in Parkinson's disease also has become a major focus of my research interest. Characterization of the clinical profile of GI dysfunction in Parkinson's disease has been undertaken and experimental treatment protocols also developed. More recently, collaborative studies investigating the underlying pathophysiology of GI dysfunction in Parkinson's disease have been instituted.

We are also investigating, via primary cell culture techniques, possible toxic factors to dopamine neurons along with studies of cytoskeletal changes that may have relevance to Lewy body formation.

Representative Publications

  • Pfeiffer RF. Gastrointestinal Involvement in Parkinson's Disease: The Horse or the Cart. Acta Physiol (Oxf). 2014 Apr 15. doi: 10.1111/apha.12300. [Epub ahead of print] PubMed PMID: 24731168.
  • The Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol. 2014 Mar 24. doi: 10.1001/jamaneurol.2014.131. [Epub ahead of print] PubMed PMID: 24664227.
  • Pfeiffer RF. Neurologic manifestations of malabsorption syndromes. Handb Clin Neurol. 2014;120:621-32. doi: 10.1016/B978-0-7020-4087-0.00042-5. PubMed PMID: 24365342.
  • Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498. PubMed PMID: 24190026; PubMed Central PMCID: PMC3947132.
  • Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30. PubMed PMID: 24123224.
  • Cheshire WP, Pfeiffer RF. Is α-synuclein rising to the surface as a diagnostic biomarker for Parkinson disease? Neurology. 2013 Oct 29;81(18):1568-9. doi: 10.1212/WNL.0b013e3182a9f5ab. Epub 2013 Oct 2. PubMed PMID: 24089391.

View more references (pubmed link)